

# Valentina Gambardella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/517644/publications.pdf>

Version: 2024-02-01

41  
papers

1,102  
citations

777949

13  
h-index

620720

26  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1984  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with <i>PIK3CA</i>-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1052-1052.	0.8	4
2	Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. <i>Future Oncology</i> , 2022, 18, 2639-2649.	1.1	14
3	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 994.	1.7	29
4	Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with <i>PIK3CA</i> mutation (mut) status from a phase I/1b study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). <i>Cancer Research</i> , 2021, 81, PS5-12-PS5-12.	0.4	2
5	Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1433.	1.7	4
6	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	2.9	14
7	In the literature: February 2020. <i>ESMO Open</i> , 2020, 5, e000680.	2.0	0
8	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020, 5, e000847.	2.0	21
9	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020, 9, 3049.	1.0	12
10	In the literature: June 2020. <i>ESMO Open</i> , 2020, 5, e000832.	2.0	0
11	In the literature: August 2020. <i>ESMO Open</i> , 2020, 5, e000909.	2.0	0
12	In the literature: December 2019. <i>ESMO Open</i> , 2020, 5, e000642.	2.0	0
13	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. <i>ESMO Open</i> , 2020, 5, e000929.	2.0	4
14	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020, 12, 3611.	1.7	30
15	In the literature: April 2020. <i>ESMO Open</i> , 2020, 5, e000749.	2.0	0
16	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	1.7	123
17	Aurora kinases in ovarian cancer. <i>ESMO Open</i> , 2020, 5, e000718.	2.0	15
18	In the literature: October 2020. <i>ESMO Open</i> , 2020, 5, e001048.	2.0	0

#	ARTICLE	IF	CITATIONS
19	ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 9339.	1.6	11
20	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. <i>Methods for detection and clinical and pathological implications. ESMO Open</i> , 2019, 4, e000470.	2.0	35
21	In the literature: February 2019. <i>ESMO Open</i> , 2019, 4, e000490.	2.0	0
22	In the literature: October 2019. <i>ESMO Open</i> , 2019, 4, e000613.	2.0	0
23	In the literature: June 2019. <i>ESMO Open</i> , 2019, 4, e000547.	2.0	3
24	In the literature: August 2018. <i>ESMO Open</i> , 2019, 4, e000563.	2.0	0
25	In the literature: April 2019. <i>ESMO Open</i> , 2019, 4, e000513.	2.0	0
26	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in <i>HER2</i> -Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1639-1649.	3.2	47
27	Breast cancer in pregnant patients: A review of the literature. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 230, 222-227.	0.5	23
28	Precision medicine in the adjuvant treatment of gastric cancer. <i>Lancet Oncology</i> , The, 2018, 19, 583-584.	5.1	22
29	In the literature: December 2018. <i>ESMO Open</i> , 2018, 3, e000468.	2.0	0
30	In the literature: June 2018. <i>ESMO Open</i> , 2018, 3, e000401.	2.0	0
31	In the literature: August 2018. <i>ESMO Open</i> , 2018, 3, e000427.	2.0	0
32	In the literature: April 2018. <i>ESMO Open</i> , 2018, 3, e000362.	2.0	0
33	In the literature: October 2018. <i>ESMO Open</i> , 2018, 3, e000447.	2.0	0
34	Personalised Treatment in Gastric Cancer: Myth or Reality?. <i>Current Oncology Reports</i> , 2016, 18, 41.	1.8	16
35	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 449-456.	1.5	7
36	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016, 7, 63424-63436.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.	1.4	94
38	Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015, 8, 1053.	1.0	6
39	Treatment of gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 1635.	1.4	508
40	Clinical management of advanced gastric cancer: The role of new molecular drugs. <i>World Journal of Gastroenterology</i> , 2014, 20, 14537.	1.4	41
41	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013, 5, 49.	0.9	5